Prostatic Neoplasms, Castration-Resistant Completed Phase 1 Trials for Apalutamide (DB11901)

IndicationStatusPhase
DBCOND0001230 (Prostatic Neoplasms, Castration-Resistant)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02162836A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate CancerTreatment